Company intelligence / Profile preview

Caelum Biosciences

Bordentown, New Jersey, United Statesastrazeneca.com ↗

Ownership: Private
Development stage: Phase 3

Overview

CAEL-101 demonstrated improved organ function, including cardiac and renal function, in 27 patients with relapsed and refractory AL amyloidosis who had not previously had an organ response to standard of care therapy in a Phase 1a/1b study. The drug is currently in Phase 3 clinical trials.

Therapeutic areas: Hematology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

CAEL-101

Phase 3

Indications: AL amyloidosis

Partnerships

Alexion Pharmaceuticals (now part of AstraZeneca)

Beyond the preview

Go deeper on Caelum Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caelum Biosciences.

Explore the full profile